Arcera Life Sciences and Fosun Pharma Form Strategic Partnership to Bridge Chinese Innovation with Global Markets
核心洞察
Arcera Life Sciences (搜索) and Fosun Pharma signed a Memorandum of Understanding to establish a long-term strategic collaboration focused on licensing, technology development, and neuroscience innovation.
The partnership will explore three key areas: regional and global licensing of Fosun Pharma assets in oncology and neuroscience, frontier technology incubation across multiple therapeutic modalities, and strategic collaboration in neurodegenerative diseases including Alzheimer's programs.
The collaboration positions Abu Dhabi as a bridge between Chinese biotech innovation and global markets, combining Fosun Pharma's R&D capabilities with Arcera's international commercial infrastructure.
Arcera Life Sciences (搜索), a global life sciences company headquartered in Abu Dhabi, and Shanghai Fosun Pharmaceutical Group Co., Ltd. announced the signing of a Memorandum of Understanding to establish a long-term strategic collaboration focused on licensing, technology development, neuroscience innovation and value creation in the global life sciences sector. The partnership, announced on April 28, 2026, aligns with the Comprehensive Strategic Partnership between China and the UAE and Abu Dhabi's Healthcare Life Sciences Vision 2030 objectives.
Strategic Framework Across Three Key Areas
The collaboration will explore three primary areas of cooperation. Regional and global licensing of assets will initially focus on identifying potential licensing opportunities for Fosun Pharma assets in oncology, neuroscience, rare diseases and cardiometabolic disease, including compounds currently in advanced clinical development or commercial stages in China.
Frontier technology incubation represents the second pillar, involving exploration of joint ventures or new entities to localize cutting-edge biotechnology and foster sovereign R&D capabilities in the UAE across small molecules, biologics, radiopharmaceuticals, small interfering RNA therapies, and cell and gene therapies.
The third area centers on strategic collaboration in neuroscience, with particular focus on neurodegenerative diseases, including Alzheimer's disease programs. This addresses what the companies describe as a critical global health challenge where both innovative therapeutics and regional access remain significant unmet needs.
Leadership Perspectives on Global Market Access
Isabel Afonso, CEO of Arcera, emphasized the partnership's role in building a global life sciences ecosystem. "Today marks another step forward in our journey to build a truly global life sciences ecosystem anchored in the UAE," Afonso stated. "By combining Fosun Pharma's proven drug development capabilities with Arcera's international commercial and manufacturing capabilities, we are creating a model for how China-UAE collaboration can accelerate both biotechnology innovation and patient access to breakthrough therapies."
Xingli Wang, Co-President of Fosun Pharma and CEO of Innovative Medicines Division, highlighted the milestone's significance for international expansion. "We are excited to establish this strategic partnership with Arcera, which marks a pivotal milestone for Fosun Pharma in deepening international collaboration and expanding into global markets," Wang said. "We are confident that our systematic capabilities built over more than 30 years in global R&D and manufacturing, will instill greater confidence in our collaboration."
Company Capabilities and Market Reach
Arcera Life Sciences (搜索) operates with a large footprint reaching patients in over 90 markets, with manufacturing and packaging facilities in eight countries, offering more than 2,000 medicines across various therapeutic areas worldwide. The company was established by ADQ (搜索), an active sovereign investor focused on critical infrastructure and global supply chains, to realize Abu Dhabi's ambition as a global leader in innovative and sustainable healthcare.
Fosun Pharma, founded in 1994, has established a global R&D innovation system targeting unmet medical needs with strategic focus on oncology, immunology and inflammation, neurodegenerative diseases, and selected cardiometabolic diseases and rare diseases. The company has consolidated core technical platforms including antibodies and antibody-drug conjugates (ADC), small molecules and cell therapy, while actively advancing cutting-edge therapeutic modalities such as radiopharmaceuticals and small nucleic acids.
Global Market Positioning
The collaboration positions Abu Dhabi as a premier bridge between Chinese biotech innovation and global markets while accelerating patient access to breakthrough therapies across the Middle East and beyond. Fosun Pharma's innovative products are currently available in more than 90 countries and regions worldwide, including major markets across China, the United States, Europe, Africa, India and Southeast Asia.
The partnership creates pathways for innovation and market access in both countries, combining Fosun Pharma's world-class R&D and manufacturing capabilities with Arcera's international market access and commercial infrastructure. This strategic framework represents Arcera's first strategic partnership designed to position Abu Dhabi as the bridge between Asian innovation and global markets.